Ahmad Masri, MD, FACC
Director, Hypertrophic Cardiomyopathy Center
OHSU

Printed as of 11/24/2026

Disclosures

Personal Commercial (19)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Alexion	Consultant Fees/Honoraria	Significant (>= $5,000)	
Alnylam	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= $5,000)	
Attralus	Consultant Fees/Honoraria	Significant (>= $5,000)	
Bayer	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
BMS	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Braveheart	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Cytokinetics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Edgewise	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Eidos	Consultant Fees/Honoraria	Significant (>= $5,000)	
Haya	Consultant Fees/Honoraria	Significant (>= $5,000)	
Imbria	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Ionis	Consultant Fees/Honoraria	Significant (>= $5,000)	
Ionis	Research/Research Grants	Significant (>= $5,000)	
Lexicon	Consultant Fees/Honoraria	Significant (>= $5,000)	
Neurimmune	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Pfizer	Consultant Fees/Honoraria	Modest (< $5,000)	
Pfizer Inc	Research/Research Grants	Significant (>= $5,000)	
Rocket	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/14/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/14/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/14/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.